Minor
Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg · Early-stage and Advanced HR+ Breast Cancer
Trial sites expanded: 23 → 26 locations
TerSera Therapeutics LLCPhase 1 NCT07310420 Registry history of NCT07310420 on ClinicalTrials.gov (opens the registry)